| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 458,480 | 283,255 |
| Share-based compensation | 34,994 | 22,834 |
| Depreciation and amortization | 8,085 | 5,427 |
| Amortization of intangible assets | 53,286 | 35,524 |
| Amortization of debt discount | 5,556 | 3,698 |
| Accretion of premium on marketable securities, net | 3,200 | 2,843 |
| Realized loss (gain) on marketable securities | -73 | -26 |
| Loss on disposal of equipment | 0 | 0 |
| Lease payments recognized | -680 | -510 |
| Deferred income taxes | -17,402 | 9,952 |
| Accounts receivable, net and other contract assets | 37,580 | 7,884 |
| Inventories | 16,227 | 15,126 |
| Prepaid expenses and other assets | 61,382 | 41,063 |
| Accounts payable and accrued expenses | -27,638 | -20,474 |
| Net cash provided by operating activities | 432,529 | 253,932 |
| Purchases of marketable securities | 247,355 | 242,399 |
| Proceeds from sales and maturities of marketable securities | 448,873 | 239,278 |
| Purchases of property and equipment | 5,543 | 2,513 |
| Net cash provided by (used in) investing activities | 195,975 | -5,634 |
| Repurchase of common stock | 342,372 | 303,489 |
| Proceeds from issuance of common stock under equity incentive plans, net of taxes paid related to net share settlement | 17,683 | 1,202 |
| Net cash (used in) provided by financing activities | -324,689 | -302,287 |
| Net increase in cash and cash equivalents | 303,815 | -53,989 |
| Cash and cash equivalents at beginning of period | 115,850 | - |
| Cash and cash equivalents at end of period | 419,665 | - |
HALOZYME THERAPEUTICS, INC. (HALO)
HALOZYME THERAPEUTICS, INC. (HALO)